Light AI announces New Director Appointments

Company enhances Board of Directors with addition of Medical Technology and Capital Markets Veterans

Vancouver, B.C. – October 21, 2025 – Light AI Inc. ("**Light AI**" or the "**Company**") (CBOE CA: ALGO / FSE: 0HC / OTCQB: OHCFF), a healthcare technology company focused on developing artificial intelligence ("AI") health diagnostic and wellness solutions, today announced the appointment of two new directors to its board of directors, Mr. Robert Cartagena and Mr. Mario Vetro.

Robert Cartagena is co-founder and managing partner of Mill Street Equity Partners LLC (formerly Mill Street Partners LLC), a specialty investment strategy development firm focused on middle-market dental and medical device companies. Robert had a 33-year career as a C-level executive and or board member for various dental manufacturing companies including Discus Dental LLC and DenMat Holdings LLC, serving as Chief Operating Officer for each firm. At both companies Robert led the development and launch of products which are now household brands in the dental industry in product categories such as surgical lasers, dental materials, professional teeth whitening, magnification and more. He has created tremendous value at various companies through new product development, sales and marketing, as well as buy-side and sell-side M&A in both private and public environments.

Mario Vetro brings substantial expertise in structuring and raising capital for growth companies with a focus on technology and the natural resources sector. He currently serves as CEO of Commodity Partners Inc, a boutique merchant bank and advisory firm. There, he played a pivotal role in the co-founding of K92 Mining Inc., a company listed on the TSX, leading to the establishment of a world-class gold discovery and mining operation in Papua New Guinea. Building upon this success, Mr. Vetro excels at assembling formidable leadership teams, securing equity capital, and devising strong business strategies.

The Company also announces the Mr. Hugh Cleland is transitioning from the Company's Board of Directors due to health reasons. Mr. Cleland has been instrumental in the Company's transition to a public company and supporting the Company in its financing and investor relations initiatives.

"Light AI is excited to welcome Robert Cartagena and Mario Vetro to its board of directors who bring extensive experience from their respective industries," stated Mr. Steven Semmelmayer, Light AI Chair of the Board of Directors. "Mr. Cartagena's executive leadership roles building and operating global medical technology companies over the past thirty years will be instrumental in supporting the Company's transition from research and development to commercialization while Mr. Vetro brings significant capital markets and corporate finance experience to support the Company in this manner. I would like to thank Mr. Cleland for his efforts in supporting the Company during his tenure as a director."

About Light AI Inc. (CBOE CA: ALGO / FSE: 0HC / OTCQB: OHCFF)

Light AI Inc. is a technology company focused on developing artificial intelligence health screening and diagnostic solutions. Light AI is developing a technology platform which represents the next generation of patient management: it applies AI algorithms to smartphone images—starting with images of Strep A and anticipated expansion with COVID19 along with other medical conditions —to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind—its hardware platform is the 4.5 billion smartphones that exist in the world today. Light AI is at the forefront of developing innovative screening and diagnostic solutions aimed at improving healthcare delivery worldwide. Their cutting-edge AI powered technology offers rapid, accurate, and cost-effective screening and diagnostic tools designed to address critical healthcare challenges.

In pre-FDA validation studies, Light AI's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (GAS). The algorithm achieved a 96.57% accuracy rate and attained a Negative Predictive Value of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (RHD), which imposes a global economic burden exceeding $1 trillion annually. Light AI's technology offers a significant advancement in the accurate and timely identification of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI's approach to applying AI to smartphone images can be expanded to other throat conditions, as well as other areas of analysis, such as the human eye and skin. Light AI's vision is to combine the smartphone with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.

ON BEHALF OF THE COMPANY

"George Reznik"
George Reznik
Chief Financial Officer
Telephone: 604-307-6800
Email: greznik@light.ai

For more information, please contact the Company at investors@light.ai or visit https://light.ai/.

Website: https://light.ai/
LinkedIn: LinkedIn/company/Light AI
X (Formerly Twitter): @lightaihealth

Forward-Looking Information:

This news release includes information, statements, beliefs and opinions which are forward-looking, and which reflect current estimates, expectations and projections about future events, including, but not limited to, the Company's research and development and commercialization initiatives, the anticipated inflection of the business, the Company's financial and operational performance and outlook and other statements that contain words such as "believe," "expect," "project," "should," "seek," "anticipate," "will," *"intend," "positioned," "risk," "plan," "may," "estimate" or, in each case, their negative and words of similar meaning. By its nature, forward-looking information involves a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking information. These risks, uncertainties and assumptions could adversely affect the outcome of the plans and events described herein. Readers should not place undue reliance on forward-looking information, which is based on the information available as of the date of this news release. For a list of the factors that may affect any of the Company's forward-looking statements, please refer to the Company's annual information form dated April 14, 2025 and other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed under its SEDAR+ profile at www.sedarplus.ca). Light AI disclaims any intention or obligation to update or revise any forward-looking information contained in this news release, whether as a result of new information, future events or otherwise, unless required by applicable law. The forward-looking information included in this news release is expressly qualified in its entirety by this cautionary statement.*